We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Rapid 45-Minute COVID-19 Test Ideal for Screening at Points of Risk

By LabMedica International staff writers
Posted on 09 Jul 2020
Print article
Image: Dr. Laura Lamb (Photo courtesy of Beaumont Research Institute)
Image: Dr. Laura Lamb (Photo courtesy of Beaumont Research Institute)
Researchers at the Aikens Research Center at Beaumont Research Institute (Southfield, MI, USA) who developed the test found the results to be highly accurate as compared to existing technology. Additionally, the rapid test is also relatively inexpensive to develop and operate as the materials for it are inexpensive and it does not require expensive machinery to run.

The researchers adapted the same technology for the COVID-19 test that they had come up with for a rapid, Zika virus detection test about three years ago. The detection test builds on recommendations from Anthony Fauci, M.D., immunologist and director of the National Institute of Allergy and Infectious Diseases since 1984, that rapid testing and tracing are the keys to containing the coronavirus. The researchers are now focusing on securing corporate sponsorship to fund development of the COVID-19 test.

According to Laura Lamb, Ph.D., who led the team, the test “could be used for screening at the point of risk, such as nursing homes, long-term care facilities, cruise ships, naval ships, within the school and prison systems, and by large employers, for example, at an Amazon warehouse or meatpacking plant. Because this is an existing test, we are optimistic with the right resources, it could be ready for widespread use within a month or so.”

Related Links:
Beaumont Research Institute

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.